Theravance Biopharma to Participate in Upcoming Investor Conferences
Theravance Biopharma (NASDAQ: TBPH) said management will participate in two investor conferences in December 2025: a Fireside Chat at the Evercore Healthcare Conference on Dec 4, 2025, 8:20–8:40 AM ET in Coral Gables, FL (live webcast), and a Panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, 2:15–2:45 PM ET in New York. Theravance will be available for one-on-one meetings at both events. Interested investors should contact their representatives to request meetings. The Evercore webcast will be accessible on the company Events and Presentation investor page with a replay archived for 30 days.
Theravance Biopharma (NASDAQ: TBPH) ha dichiarato che la direzione parteciperà a due conferenze per investitori nel dicembre 2025: una Fireside Chat presso l'Evercore Healthcare Conference il 4 dicembre 2025, 8:20–8:40 AM ET a Coral Gables, FL (trasmissione web in diretta), e un Panel al Summit Oppenheimer Movers in Rare Disease il 11 dicembre 2025, 14:15–14:45 ET a New York. Theravance sarà disponibile per incontri one-on-one in entrambi gli eventi. Gli investitori interessati dovrebbero contattare i loro rappresentanti per richiedere incontri. La webcast di Evercore sarà accessibile sulla pagina Events and Presentation degli investitori dell'azienda con una replica archiviata per 30 giorni.
Theravance Biopharma (NASDAQ: TBPH) dijo que la dirección participará en dos conferencias para inversores en diciembre de 2025: una Fireside Chat en la Evercore Healthcare Conference el 4 de diciembre de 2025, 8:20–8:40 AM ET en Coral Gables, FL (transmisión en vivo por web), y un Panel en la cumbre Oppenheimer Movers in Rare Disease Summit de Oppenheimer el 11 de diciembre de 2025, 14:15–14:45 PM ET en Nueva York. Theravance estará disponible para reuniones uno a uno en ambos eventos. Los inversores interesados deben contactar a sus representantes para solicitar reuniones. La webcast de Evercore estará accesible en la página de inversores Events and Presentation de la empresa con una repetición archivada por 30 días.
Theravance Biopharma (NASDAQ: TBPH)은 2025년 12월 두 차례의 투자자 컨퍼런스에 경영진이 참여할 것이라고 밝혔다: Evercore Healthcare Conference의 Fireside Chat가 2025년 12월 4일, 8:20–8:40 AM ET 플로리다주 코랄 게이블스에서 라이브 웨 webcast, 그리고 Panel이 Oppenheimer Movers in Rare Disease Summit의 세션으로 2025년 12월 11일, 2:15–2:45 PM ET 뉴욕에서 개최된다. Theravance는 두 행사 모두에서 일대일 미팅을 위해 이용 가능할 것이다. 관심 있는 투자자는 미팅 요청을 담당자에게 연락해야 한다. Evercore 웹캐스트는 회사의 Events and Presentation 투자자 페이지에서 이용 가능하며 30일 동안 재생이 아카이브되어 있다.
Theravance Biopharma (NASDAQ: TBPH) a déclaré que la direction participera à deux conférences pour investisseurs en décembre 2025 : un Fireside Chat à l'Evercore Healthcare Conference le 4 décembre 2025, 8:20–8:40 AM ET à Coral Gables, FL (webcast en direct), et un Panel au sommet Oppenheimer Movers in Rare Disease Summit le 11 décembre 2025, 14:15–14:45 PM ET à New York. Theravance sera disponible pour des rencontres en tête-à-tête lors des deux événements. Les investisseurs intéressés devraient contacter leurs représentants pour demander des rendez-vous. Le webcast Evercore sera accessible sur la page Events and Presentation des investisseurs de l’entreprise avec une rediffusion archivées pour 30 jours.
Theravance Biopharma (NASDAQ: TBPH) sagte, das Management werde an zwei Investorenkonferenzen im Dezember 2025 teilnehmen: ein Fireside Chat bei der Evercore Healthcare Conference am 4. Dezember 2025, 8:20–8:40 AM ET in Coral Gables, FL (Live-Webcast), und ein Panel bei der Oppenheimer Movers in Rare Disease Summit am 11. Dezember 2025, 14:15–14:45 PM ET in New York. Theravance wird für Einzelgespräche bei beiden Veranstaltungen zur Verfügung stehen. Interessierte Investoren sollten ihre Vertreter kontaktieren, um Meetings zu vereinbaren. Der Evercore-Webcast wird auf der Events and Presentation-Seite der Investoren des Unternehmens verfügbar sein und eine 30 Tage lang archivierte Wiedergabe bieten.
Theravance Biopharma (NASDAQ: TBPH) قالت الإدارة إنها ستشارك في مؤتمرين للمستثمرين في ديسمبر 2025: Fireside Chat في Evercore Healthcare Conference بتاريخ 4 ديسمبر 2025، 8:20–8:40 صباحاً بتوقيت شرق الولايات المتحدة في كورال جيبلز، فلوريدا (البث المباشر عبر الويب)، و< b>Panel في قمة Oppenheimer Movers in Rare Disease Summit بتاريخ 11 ديسمبر 2025، 2:15–2:45 مساءً بتوقيت شرق الولايات المتحدة في نيويورك. ستكون Theravance متاحة للاجتماعات ثنائية الاتجاه في كلا الحدثين. يجب على المستثمرين المهتمين التواصل مع ممثليهم لطلب الاجتماعات. سيكون البث المباشر لـ Evercore متاحاً على صفحة Events and Presentation للمستثمرين بالشركة مع إعادة تشغيل مؤرشفة لمدة 30 يوماً.
- None.
- None.
8th Annual Evercore Healthcare Conference
Location:
Format: Fireside Chat
Date: Thursday, December 4, 2025
Time: 8:20-8:40 AM ET
Webcast
Oppenheimer Movers in Rare Disease Summit
Location:
Format: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts
Date: Thursday, December 11, 2025
Time: 2:15-2:45 PM ET
Theravance will be available for one-on-one meetings during both events. Interested investors should contact their respective representatives to request meetings.
A live webcast of the Evercore presentation may also be accessed on the "Events and Presentation" page under the Investors section on Theravance.com. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the
YUPELRI® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-upcoming-investor-conferences-302619765.html
SOURCE Theravance Biopharma, Inc.
FAQ
When will Theravance Biopharma (TBPH) present at the Evercore Healthcare Conference in December 2025?
How can investors watch TBPH's Evercore presentation webcast?
When and where will TBPH participate in the Oppenheimer Movers in Rare Disease Summit?
Can investors request one-on-one meetings with TBPH management at these December 2025 events?
Will TBPH make presentation materials available after the events in December 2025?
What topics will TBPH cover at the Rare Disease panel on Dec 11, 2025?
